ImmunoGen, Inc. and Protagonist Therapeutics, Inc. accomplished in early April what has become increasingly difficult for public biotechnology companies to do when they accessed significant amounts of new capital to fund ongoing research and development and, in the case of ImmunoGen, commercial activities. These feats were achieved as many more of their peers were revealing plans to cut costs, implement layoffs and even file for bankruptcy.
Waltham, MA-based ImmunoGen said on 6 April that it entered into a term loan facility for up to $175m with...
